Tiger Securities: Big Mac ants listed, bio medicine piled up, IPO market of Hong Kong stock raised a boom again

category:Internet
 Tiger Securities: Big Mac ants listed, bio medicine piled up, IPO market of Hong Kong stock raised a boom again


In addition to ant group, blue moon, the 28 year old leader of domestic cleaning products, will also be a major focus of the IPO market in Hong Kong stock market. According to the prospectus, blue moon brand ranked first in Chinas detergent market and hand sanitizer market for 10 consecutive years (2011-2020). From 2017 to 2019, the companys revenue was 5.63 billion yuan, 6.77 billion yuan and 7.05 billion yuan respectively. Over the same period, the companys net profits were 86.16 million yuan, 550 million yuan and 1.08 billion yuan respectively. Previously, some media said that blue moon planned to carry out a $1 billion IPO, which also means that Chinas domestic detergent stock may be born.

In addition to the companies that have already been disclosed, it has been reported recently that Yum China, which has exclusive rights to KFC and pizza hut in China, has submitted its listing application to the Hong Kong Stock Exchange in a confidential form. The IPO process will start as soon as next week, and it is expected to be officially listed in Hong Kong in September. According to the news, the fund-raising will reach 2 billion US dollars.

New economy company is ready to go

At the same time, companies in the new economy, technology and other industries are also rubbing their hands, waiting for the magnesium lamp to light up.

Bubble mart, a leading fashion culture and entertainment company in the world, has applied to the Hong Kong stock exchange. According to frost Sullivan, the company is the largest and fastest growing fashion toy company in China based on its revenue in 2019 and its revenue growth from 2017 to 2019. IP is the core of its business. Bubble Mart said in its prospectus that it has established an integrated platform covering the whole industry chain of fashion toys, including artist discovery, IP operation, consumer touch and promotion of fashion toy culture. From 2017 to 2019, the revenue of bubble mart is 160 million yuan, 510 million yuan and 1.68 billion yuan respectively, and the net profit is 1.57 million yuan, 99.52 million yuan and 450 million yuan.

In addition, the largest interactive media service provider in China is expected to offer official account soon. The company has served 3806 WeChat public numbers as of March 31, 2020 and has more than 733 million fans. According to media reports, many new economic companies, such as tiktok, jitter, and the byelt beating of headlines, are considering promoting the listing in Hong Kong.

Since the amendment of listing rules by the Hong Kong stock exchange, in addition to embracing the new economy industry, it has also opened the door for companies in the biotechnology industry to go public, even if some companies have not made profits or have not. As a result, the ecology of the Hong Kong stock market has been greatly changed in two years, and has become the first choice for many biomedical companies to be listed. Since the second half of the year, the Hong Kong Stock Exchange has successively welcomed companies such as tiger pharmaceutical and o-comview, which not only received hot subscription from investors, but also brought considerable returns to investors from the perspective of stock price. For example, Taige medicine, which oversubscribed more than 400 times, rose 19% in the opening session, while oukangweishi, which received 1895.76 times of subscription, rose 193% on the first day.

Among them, the clinical stage cell therapy platform company, myjuno, is co sponsored by Goldman Sachs and UBS. Its main candidate product, relma cel, is an anti-cd19car-t therapy for relapsed or refractory (R / R) B-cell lymphoma. In June 2020, the State Food and drug administration has accepted and reviewed its new drug application for using relma cel as the third line therapy of DLBCL. According to the prospectus, relma cel is expected to become the first class I biological product car-t therapy approved in China, and is expected to become the best car-t therapy of its kind. According to the prospectus, another platinum medicine company, which is engaged in research and development of new and highly differentiated antibody therapy in the field of immunity and tumor diseases, is co sponsored by Morgan Stanley, BofA securities and CITIC Securities. As of June 30, 2020, six projects have entered the clinical stage. Although the company has not made profits as of June 2020, it has a strong background of shareholders before listing, including CDH investment, Shangyin capital, SK holding of South Korea, GIC of Singapore government investment company, etc. Source: editor in charge of mass news: Chen Tiqiang_ NB6485

Among them, the clinical stage cell therapy platform company, myjuno, is co sponsored by Goldman Sachs and UBS. Its main candidate product, relma cel, is an anti-cd19car-t therapy for relapsed or refractory (R / R) B-cell lymphoma. In June 2020, the State Food and drug administration has accepted and reviewed its new drug application for using relma cel as the third line therapy of DLBCL. According to the prospectus, relma cel is expected to become the first class I biological product car-t therapy approved in China, and is expected to become the best car-t therapy of its kind.

According to the prospectus, another platinum medicine company, which is engaged in research and development of new and highly differentiated antibody therapy in the field of immunity and tumor diseases, is co sponsored by Morgan Stanley, BofA securities and CITIC Securities. As of June 30, 2020, six projects have entered the clinical stage. Although the company has not made profits as of June 2020, it has a strong background of shareholders before listing, including CDH investment, Shangyin capital, SK holding of South Korea, GIC of Singapore government investment company, etc.